Bacchus Amir

SEC source: 0001628280-24-001542 · wk-form4_1705530386.xml · nonDerivative · entry 1

Bacchus Amir · CIK 0001890100 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,005,193

F1 · kind: On January 3, 2024, the Reporting Person filed a Form 4 reporting the withholding of 287,118 shares of Class A common stock to satisfy tax withholding requirements upon the vesting of restricted stock units. On January 9, 2024, the withholding was rescinded upon election by the Reporting Person to satisfy tax withholding obligations via a cash payment and no shares were withheld.

F1 · price: On January 3, 2024, the Reporting Person filed a Form 4 reporting the withholding of 287,118 shares of Class A common stock to satisfy tax withholding requirements upon the vesting of restricted stock units. On January 9, 2024, the withholding was rescinded upon election by the Reporting Person to satisfy tax withholding obligations via a cash payment and no shares were withheld.

SEC source: 0001628280-24-000269 · wk-form4_1704321074.xml · nonDerivative · entry 1

Bacchus Amir · CIK 0001890100 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,718,075

F1 · shares: Represents shares withheld by the Issuer to satisfy tax withholding requirements on vesting of restricted stock units.

SEC source: 0001104659-23-088999 · tm2323184-3_4seq1.xml · nonDerivative · entry 1

Bacchus Amir · CIK 0001890100 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,005,193

F1 · shares: Represents a grant of restricted stock units ("RSUs") granted pursuant to the P3 Health Partners Inc. 2021 Incentive Award Plan in full satisfaction of the "Second Bonus" set forth in the Transaction Bonus Agreement between Reporting Person, the Issuer and P3 Health Group Management, LLC, dated May 2022. Each RSU represents a right to receive one share of Class A common stock. The RSUs will be settled in Class A common stock on the earlier of (i) December 31, 2023 and (ii) the closing of the Company's first underwritten offering and sale of common stock.

SEC source: 0001104659-23-043700 · tm2312243-1_4seq1.xml · derivative · entry 6

Bacchus Amir · CIK 0001890100 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Charlee Co LLC

Disclosed balance after: 188,474

Underlying: Class A Common Stock · 188,474 shares

Expires 2028-04-05

F2 · shares: The reported securities were issued in connection with the Issuer's sale of 251,298 Units purchased by the Reporting Person for $1.1938 per Unit. Each Unit consists of (i) one share of Class A Common Stock and (ii) 0.75 of a warrant to purchase one share of Class A Common Stock.

F2 · price: The reported securities were issued in connection with the Issuer's sale of 251,298 Units purchased by the Reporting Person for $1.1938 per Unit. Each Unit consists of (i) one share of Class A Common Stock and (ii) 0.75 of a warrant to purchase one share of Class A Common Stock.

F4 · derivative.exercise_date: Exercisable Immediately.

F3 · ownership.nature: These shares are held directly by Charlee Co LLC, an entity for which the Reporting Person serves as managing member.

SEC source: 0001104659-23-043700 · tm2312243-1_4seq1.xml · derivative · entry 5

Bacchus Amir · CIK 0001890100 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 753,895

Underlying: Class A Common Stock · 753,895 shares

Expires 2028-04-05

F1 · shares: The reported securities were issued in connection with the Issuer's sale of 1,005,193 Units purchased by the Reporting Person for $1.1938 per Unit. Each Unit consists of (i) one share of Class A Common Stock and (ii) 0.75 of a warrant to purchase one share of Class A Common Stock.

F1 · price: The reported securities were issued in connection with the Issuer's sale of 1,005,193 Units purchased by the Reporting Person for $1.1938 per Unit. Each Unit consists of (i) one share of Class A Common Stock and (ii) 0.75 of a warrant to purchase one share of Class A Common Stock.

F4 · derivative.exercise_date: Exercisable Immediately.

SEC source: 0001104659-23-043700 · tm2312243-1_4seq1.xml · nonDerivative · entry 2

Bacchus Amir · CIK 0001890100 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Charlee Co LLC

Disclosed balance after: 251,298

F2 · shares: The reported securities were issued in connection with the Issuer's sale of 251,298 Units purchased by the Reporting Person for $1.1938 per Unit. Each Unit consists of (i) one share of Class A Common Stock and (ii) 0.75 of a warrant to purchase one share of Class A Common Stock.

F2 · price: The reported securities were issued in connection with the Issuer's sale of 251,298 Units purchased by the Reporting Person for $1.1938 per Unit. Each Unit consists of (i) one share of Class A Common Stock and (ii) 0.75 of a warrant to purchase one share of Class A Common Stock.

F3 · ownership.nature: These shares are held directly by Charlee Co LLC, an entity for which the Reporting Person serves as managing member.

SEC source: 0001104659-23-043700 · tm2312243-1_4seq1.xml · nonDerivative · entry 1

Bacchus Amir · CIK 0001890100 · Director · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,005,193

F1 · shares: The reported securities were issued in connection with the Issuer's sale of 1,005,193 Units purchased by the Reporting Person for $1.1938 per Unit. Each Unit consists of (i) one share of Class A Common Stock and (ii) 0.75 of a warrant to purchase one share of Class A Common Stock.

F1 · price: The reported securities were issued in connection with the Issuer's sale of 1,005,193 Units purchased by the Reporting Person for $1.1938 per Unit. Each Unit consists of (i) one share of Class A Common Stock and (ii) 0.75 of a warrant to purchase one share of Class A Common Stock.

SEC source: 0001104659-21-147361 · tm2134662-4_4seq1.xml · derivative · entry 4

Bacchus Amir · CIK 0001890100 · Director · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Charlee Co LLC

Disclosed balance after: 3,758,130

Underlying: Class A Common Stock · 3,758,130 shares

Expires not disclosed

F3 · security: At the closing of the business combination pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), as described in the Issuer's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on October 28, 2021, as supplemented, the reporting person received Common Units of P3 Health Group, LLC (the "Common Units"), a direct subsidiary of the Issuer, as consideration for the common units of P3 Health Group Holdings, LLC. In connection with the receipt of Common Units, each recipient subscribed for an equal number of shares of Class V Common Stock of the Issuer for a purchase price equal to par value.

F4 · derivative.exercise_price: The Common Units are redeemable at any time by the reporting person for, at the election of the Issuer, newly-issued Class A Common Stock of the Issuer on a one-for-one basis or a cash payment equal to the volume weighted average market price of one share of Class A Common Stock for each Common Unit redeemed. Upon the redemption of any Common Units, a number of shares of Class V Common Stock of the Issuer equal to the number of Common Units that are redeemed will be cancelled by the Issuer for no consideration.

F5 · shares: Includes 353,739 shares of Class V common stock and 353,739 Common Units of P3 Health Group, LLC being held in escrow following the business combination described above until the resolution of a dispute among the former unitholders of P3 Health Group Holdings, LLC in accordance with the Merger Agreement.

F3 · price: At the closing of the business combination pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), as described in the Issuer's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on October 28, 2021, as supplemented, the reporting person received Common Units of P3 Health Group, LLC (the "Common Units"), a direct subsidiary of the Issuer, as consideration for the common units of P3 Health Group Holdings, LLC. In connection with the receipt of Common Units, each recipient subscribed for an equal number of shares of Class V Common Stock of the Issuer for a purchase price equal to par value.

F4 · derivative.exercise_date: The Common Units are redeemable at any time by the reporting person for, at the election of the Issuer, newly-issued Class A Common Stock of the Issuer on a one-for-one basis or a cash payment equal to the volume weighted average market price of one share of Class A Common Stock for each Common Unit redeemed. Upon the redemption of any Common Units, a number of shares of Class V Common Stock of the Issuer equal to the number of Common Units that are redeemed will be cancelled by the Issuer for no consideration.

F4 · derivative.expiration_date: The Common Units are redeemable at any time by the reporting person for, at the election of the Issuer, newly-issued Class A Common Stock of the Issuer on a one-for-one basis or a cash payment equal to the volume weighted average market price of one share of Class A Common Stock for each Common Unit redeemed. Upon the redemption of any Common Units, a number of shares of Class V Common Stock of the Issuer equal to the number of Common Units that are redeemed will be cancelled by the Issuer for no consideration.

F5 · balance_after: Includes 353,739 shares of Class V common stock and 353,739 Common Units of P3 Health Group, LLC being held in escrow following the business combination described above until the resolution of a dispute among the former unitholders of P3 Health Group Holdings, LLC in accordance with the Merger Agreement.

F6 · ownership.nature: These shares are held directly by Charlee Co LLC, an entity for which the reporting person serves as managing member.

SEC source: 0001104659-21-147361 · tm2134662-4_4seq1.xml · derivative · entry 3

Bacchus Amir · CIK 0001890100 · Director · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,032,528

Underlying: Class A Common Stock · 15,032,528 shares

Expires not disclosed

F3 · security: At the closing of the business combination pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), as described in the Issuer's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on October 28, 2021, as supplemented, the reporting person received Common Units of P3 Health Group, LLC (the "Common Units"), a direct subsidiary of the Issuer, as consideration for the common units of P3 Health Group Holdings, LLC. In connection with the receipt of Common Units, each recipient subscribed for an equal number of shares of Class V Common Stock of the Issuer for a purchase price equal to par value.

F4 · derivative.exercise_price: The Common Units are redeemable at any time by the reporting person for, at the election of the Issuer, newly-issued Class A Common Stock of the Issuer on a one-for-one basis or a cash payment equal to the volume weighted average market price of one share of Class A Common Stock for each Common Unit redeemed. Upon the redemption of any Common Units, a number of shares of Class V Common Stock of the Issuer equal to the number of Common Units that are redeemed will be cancelled by the Issuer for no consideration.

F2 · shares: Includes 1,414,959 shares of Class V common stock and 1,414,959 Common Units of P3 Health Group, LLC being held in escrow following the business combination described below until the resolution of a dispute among the former unitholders of P3 Health Group Holdings, LLC in accordance with the Merger Agreement (as defined below).

F3 · price: At the closing of the business combination pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), as described in the Issuer's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on October 28, 2021, as supplemented, the reporting person received Common Units of P3 Health Group, LLC (the "Common Units"), a direct subsidiary of the Issuer, as consideration for the common units of P3 Health Group Holdings, LLC. In connection with the receipt of Common Units, each recipient subscribed for an equal number of shares of Class V Common Stock of the Issuer for a purchase price equal to par value.

F4 · derivative.exercise_date: The Common Units are redeemable at any time by the reporting person for, at the election of the Issuer, newly-issued Class A Common Stock of the Issuer on a one-for-one basis or a cash payment equal to the volume weighted average market price of one share of Class A Common Stock for each Common Unit redeemed. Upon the redemption of any Common Units, a number of shares of Class V Common Stock of the Issuer equal to the number of Common Units that are redeemed will be cancelled by the Issuer for no consideration.

F4 · derivative.expiration_date: The Common Units are redeemable at any time by the reporting person for, at the election of the Issuer, newly-issued Class A Common Stock of the Issuer on a one-for-one basis or a cash payment equal to the volume weighted average market price of one share of Class A Common Stock for each Common Unit redeemed. Upon the redemption of any Common Units, a number of shares of Class V Common Stock of the Issuer equal to the number of Common Units that are redeemed will be cancelled by the Issuer for no consideration.

F2 · balance_after: Includes 1,414,959 shares of Class V common stock and 1,414,959 Common Units of P3 Health Group, LLC being held in escrow following the business combination described below until the resolution of a dispute among the former unitholders of P3 Health Group Holdings, LLC in accordance with the Merger Agreement (as defined below).

SEC source: 0001104659-21-147361 · tm2134662-4_4seq1.xml · nonDerivative · entry 2

Bacchus Amir · CIK 0001890100 · Director · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Charlee Co LLC

Disclosed balance after: 3,758,130

F1 · security: Upon the redemption of any Common Units (as defined below), a number of shares of Class V Common Stock equal to the number of Common Units that are redeemed will be cancelled by the Issuer for no consideration.

F5 · shares: Includes 353,739 shares of Class V common stock and 353,739 Common Units of P3 Health Group, LLC being held in escrow following the business combination described above until the resolution of a dispute among the former unitholders of P3 Health Group Holdings, LLC in accordance with the Merger Agreement.

F3 · price: At the closing of the business combination pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), as described in the Issuer's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on October 28, 2021, as supplemented, the reporting person received Common Units of P3 Health Group, LLC (the "Common Units"), a direct subsidiary of the Issuer, as consideration for the common units of P3 Health Group Holdings, LLC. In connection with the receipt of Common Units, each recipient subscribed for an equal number of shares of Class V Common Stock of the Issuer for a purchase price equal to par value.

F5 · balance_after: Includes 353,739 shares of Class V common stock and 353,739 Common Units of P3 Health Group, LLC being held in escrow following the business combination described above until the resolution of a dispute among the former unitholders of P3 Health Group Holdings, LLC in accordance with the Merger Agreement.

F6 · ownership.nature: These shares are held directly by Charlee Co LLC, an entity for which the reporting person serves as managing member.

SEC source: 0001104659-21-147361 · tm2134662-4_4seq1.xml · nonDerivative · entry 1

Bacchus Amir · CIK 0001890100 · Director · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,032,528

F1 · security: Upon the redemption of any Common Units (as defined below), a number of shares of Class V Common Stock equal to the number of Common Units that are redeemed will be cancelled by the Issuer for no consideration.

F2 · shares: Includes 1,414,959 shares of Class V common stock and 1,414,959 Common Units of P3 Health Group, LLC being held in escrow following the business combination described below until the resolution of a dispute among the former unitholders of P3 Health Group Holdings, LLC in accordance with the Merger Agreement (as defined below).

F3 · price: At the closing of the business combination pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), as described in the Issuer's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on October 28, 2021, as supplemented, the reporting person received Common Units of P3 Health Group, LLC (the "Common Units"), a direct subsidiary of the Issuer, as consideration for the common units of P3 Health Group Holdings, LLC. In connection with the receipt of Common Units, each recipient subscribed for an equal number of shares of Class V Common Stock of the Issuer for a purchase price equal to par value.

F2 · balance_after: Includes 1,414,959 shares of Class V common stock and 1,414,959 Common Units of P3 Health Group, LLC being held in escrow following the business combination described below until the resolution of a dispute among the former unitholders of P3 Health Group Holdings, LLC in accordance with the Merger Agreement (as defined below).